Hervé Brailly, CEO, is invited to the panel discussion "French Public Markets – Breakthrough Technologies Panel".
Zurich,Switzerland
More info
Inserm Transfert and Innate Pharma enter into an innovative partnership for the development of new antibodies for the treatment of cancer and inflammatory or autoimmune diseases
September 11, 2009
- Over a three-year period, Inserm Transfert will make available to Innate Pharma information on early-stage antibody targets discovered within Inserm’s academic research laboratories, for the purpose of jointly advancing them and concluding commercial licenses.
- Over a three-year period, Inserm Transfert will make available to Innate Pharma information on early-stage antibody targets discovered within Inserm’s academic research laboratories, for the purpose of jointly advancing them and concluding commercial licenses.
| Download Area |
|---|
| PR in english |
| CP en français |